AzTrials
AzTrials

Anesthesia, ConductionNCT03449329

RCT Impact of Serratus Intercostal Plane Block in Video Assisted Thoracic Surgery

A study testing SIP in people with Anesthesia, Conduction, run by AZ Sint-Jan AV at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Rationale Video Assisted Thoracic Surgery (VATS) is known to be a moderate painful procedure. There are many ways to manage postoperative pain following this kind of surgery. One of the 'golden standards' nowadays is epidural analgesia using Patient Controlled Epidural Analgesia (PCEA). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Anesthesia, Conduction
What is being tested?
SIP
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
21 participants
Where
1 siteBelgium
Study dates
1 Apr 2018to 31 Jul 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • patients scheduled for thoracoscopic surgery

Who cannot join

  • urgent surgery
  • allergic to Sufentanil or Ropivacaine

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • Azsintjan

    Bruges, 8000

Other trials in Belgium

About this study

Official title: Randomised Controlled Double Blinded Trial Analyzing Impact of Serratus Intercostal Plane Block in Video Assisted Thoracic Surgery on Postoperative Pain and Recovery.

Rationale Video Assisted Thoracic Surgery (VATS) is known to be a moderate painful procedure. There are many ways to manage postoperative pain following this kind of surgery. One of the 'golden standards' nowadays is epidural analgesia using Patient Controlled Epidural Analgesia (PCEA). Patient Controlled Intravenous Analgesia (PCIA) is also an option, as are several kinds of regional anesthesia. One of the most recent described regional blocks is the Serratus Anterior Plane block (SAP), also called Serratus Intercostal Plane (SIP) block.

Objectives The objective of this study is to evaluate the efficacy and opioid sparing effect of a SIP block in postoperative pain relief after VATS.

Read more

Hypotheses Patients receiving a SIP block prior to surgery need less opioids during and 24h after VATS compared with patients who didn't receive a SIP block.

Study design Single center randomized controlled trial Study population Patients older than 18 years old scheduled for VATS. Main study parameters/endpoints The primary endpoint is the opioid use during the first 24 hours after start of surgery. Secondary endpoints are the VAS score on day 0 and day 1 after surgery, and the prevalence of postoperative nausea and vomiting (PONV).

Nature and extent of the burden and risks associated with participation, benefit and group relatedness In the intra-operative period, patients will not experience discomfort from either strategy because of general anesthesia. If the hypothesis proves to be true, patients with SIP block could benefit from a lower amount of received opioids, which could give less chance of opioid associated adverse effects. There won't be any additional blood sampling related to this study.

Read the detailed description

The proposed randomized controlled trial aims at comparing the opioid use per- and postoperatively in patients with versus without SIP block undergoing VATS.

We hypothesize that use of a SIP block results in less opioid use during and the first 24 hours after VATS as compared with patients without SIP block.

Single center randomized controlled trial on patients undergoing VATS under general anesthesia.

We intend to recruit patients scheduled for elective VATS in our hospital during a period of 3 months. Surgical patients will be screened twice a week, because there are two days a week that VATS procedures take place in our hospital. We will randomize 20 patients, based on the power analysis (cfr infra).

Inclusion criteria: Patients scheduled for VATS under general anesthesia Exclusion criteria

  • Age < 18 years
  • Urgent surgery
  • Allergy to sufentanil or ropivacain
  • Postoperative need for invasive ventilation within 24hours after surgery

Sample size calculation was based on our primary hypothesis and primary study outcome, and was informed by data collected in patients who underwent VATS procedures in our hospital during the previous six months. These calculations indicate that 14 patients need to be included, assuming a significance level of 0.05 and a power of 80%, to detect the expected difference in per- and postoperative opioid use between the SIP-group and the placebo group.

Main study parameter/endpoint: Opioid use during the first 24 hours after end of surgery Secondary study parameters/endpoints

  • VAS score on day 0 and day 1
  • Postoperative nausea and vomiting (PONV)

Surgical patients in our hospital will be considered eligible if they fulfill the entry criteria. Eligible patients will be screened, their demographic data recorded (registry: age, gender, type of surgery) and those without exclusion criteria will be randomized. In total, 20 patients will be included.

Patient Consent All patients or legal guardians must provide written informed consent according to local regulations before inclusion in the study.

Randomization will be performed using a sealed envelope system. Randomization arms Before surgery patients will be randomly assigned 1:1 to a placebo SIP block or to a real SIP block. All investigators involved intra- and postoperative are blinded. An independent anesthesia nurse not involved peri-operatively is asked to prepare the drugs in a different location according to the info kept in a sealed envelope. This envelope remains sealed in the patient files to be broken if an adverse event happens.

After induction of anesthesia and before surgery, each patient will receive an injection in between the serratus anterior and the intercostal muscle. The injection will be localized in the midaxillary line, between the 4th and 5th rib. The intervention group will receive a total amount of 60cc which consists of:

  • 3mg/kg Ropivacain 1%
  • 1mcg/kg dexmedetomidine (Dexdor®) (ampul with 2 ml contains 100mcg/ml)
  • Addition of NaCl 0.9% up to 60ml The control group will receive an injection of 60cc NaCl 0.9% at the same injection site of the SIP block.

Each patient will receive 5-15mcg sufentanil (Sufenta®) before induction of anesthesia, depending on the personal choice of the anesthesiologist. To induce anesthesia, patients will receive 2mg/kg propofol 1% (Propofol®), and if not sufficient, a supplemental bolus will be given. To receive adequate neuromuscular blockage, at least 0.6mg/kg rocuroniumbromide 1% (Esmeron®) will be used.

Starting from insicion, depending on the personal choice of the performing anesthesiologist or based on ANI monitoring, a supplemental bolus sufentanil will be given if considered necessary. Routine intra-operative monitoring should include noninvasive blood pressure measurements, pulse oximetry, end-tidal carbon dioxide fraction and electrocardiography. Every patient should receive at least one peripheral venous line to allow adequate fluid resuscitation during the study period. Nasogastric tubes, urinary bladder catheters and/or other intravenous catheters, as well as other, more invasive monitoring may be used according to local practice and/or guidelines.

All patients receive a PCIA pump with sufentanyl and the dose requested and given is measured for the first and the second day. Patients receive paracetamol 1 gram every 6 hours.

Data to be collected

Pre-operative variables will be collected at the pre-anesthetic visit or before induction of general anesthesia:

Intra-operative variables will be collected after induction of anesthesia and during surgery:

Postoperative variables will be collected with a patient questionnaire and clinical examination, both on day 0 en 1 after surgery. Following variables will be collected:

Patient characteristics will be compared and described by appropriate statistics. The analysis will be performed with STATA or SPSS.

Being tested
SIP

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SIPProcedure or surgery

    The intervention group will receive a SIP block

Study groups in NCT03449329
Study groupRoleWhat they receive
placebo SIP blockPlacebo comparatorThis group will receive a placebo SIP block injection with 60mL NaCl 0.9%
Receives: Procedure: SIP
Locoregional SIP blockActive comparatorThis group will receive a SIP block using: 3mg/kg Ropivacain 1% 1mcg/kg dexmedetomidine (Dexdor®) 100mcg/ml Addition of NaCl 0.9% up to 60ml
Receives: Procedure: SIP

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Opioid consumption during the first 24 hours postoperative

    total dose of opioids given

    Measured: first 24 hours postoperative (after wound closure)

Secondary outcomes (1)
  1. Intraoperative opioid consumption

    total dose of opioids used intra operative

    Measured: intra operative (from incision till wound closure)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Feb 2018
  2. Study start1 Apr 2018
  3. Primary completion30 Jun 2019
  4. Study completion31 Jul 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
double blinded randomized two study group
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
21 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03449329
Sponsor's protocol ID
RCT impact of SIPblock
Status last verified
Nov 2019
First submitted
19 Feb 2018
Last updated
19 Nov 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing SIP in people with Anesthesia, Conduction, run by AZ Sint-Jan AV at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Opioid consumption during the first 24 hours postoperative (time frame: first 24 hours postoperative (after wound closure)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in